logo

Alkermes Plc (ALKS)



Trade ALKS now with
  Date
  Headline
7/26/2018 7:07:24 AM Alkermes Q2 Loss Per Share $0.21 Vs Loss $0.28 Last Year
7/2/2018 7:02:33 AM Alkermes: FDA Approves ARISTADA INITIO For Initiation Of ARISTADA For Schizophrenia
6/6/2018 7:03:18 AM Alkermes Gets $50 Mln Payment From Biogen Following Review Of Preliminary Gastrointestinal Tolerability Data
4/30/2018 7:07:49 AM Alkermes To Present Clinical Data At Upcoming American Psychiatric Association Annual Meeting
4/26/2018 7:04:08 AM Alkermes Q1 GAAP Net Loss Per Share $0.40; Non-GAAP Loss Per Share $0.09
4/26/2018 7:03:29 AM Alkermes Completes Patient Enrollment In Pivotal Weight Study Of ALKS 3831 For Schizophrenia
4/16/2018 6:51:39 AM Alkermes Says FDA Accepts For Review Of NDA For ALKS 5461 For Adjunctive Treatment Of Major Depressive Disorder